Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

• 在研新药：以GLP-1R、THR-β、FGF21、PPAR等靶点为主，多款产品临床疗效显著。目前全球有超400款创新药正在开展NASH适应症的临 床试验，3款药物赛格 ...

due to NASH, a form of non-alcoholic fatty liver disease (NAFLD). In the 182-patient study, patients were treated with one of two doses of the FGF21 mimic or placebo - given as a once-weekly ...

Altered PPARA signaling in NASH contributes to messed-up fat processing and liver inflammation. Importantly, FGF19 and FGF21 are essential targets for drugs that regulate bile acids and energy in ...

The HARMONY study compared two doses of Akero's FGF21 mimic efruxifermin to placebo over 24 weeks in 128 adult patients with biopsy-confirmed NASH, a serious form of non-alcoholic fatty liver ...

Madrigal is likely to face competition as more NASH assets get approved, especially from the more efficacious FGF21 analogue drug class in more severe fibrotic NASH patient populations.

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.